432 related articles for article (PubMed ID: 18612674)
1. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
Arch JR
Naunyn Schmiedebergs Arch Pharmacol; 2008 Aug; 378(2):225-40. PubMed ID: 18612674
[TBL] [Abstract][Full Text] [Related]
2. Dependence of β3-adrenergic signaling on the adipokine leptin in cardiac myocytes.
Larson JE; Rainer PP; Watts VL; Yang R; Miller KL; Phan A; Barouch LA
Int J Obes (Lond); 2012 Jun; 36(6):876-9. PubMed ID: 21772246
[TBL] [Abstract][Full Text] [Related]
3. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
Arch JR
Eur J Pharmacol; 2002 Apr; 440(2-3):99-107. PubMed ID: 12007528
[TBL] [Abstract][Full Text] [Related]
4. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
Weyer C; Tataranni PA; Snitker S; Danforth E; Ravussin E
Diabetes; 1998 Oct; 47(10):1555-61. PubMed ID: 9753292
[TBL] [Abstract][Full Text] [Related]
5. Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.
Decara J; Rivera P; Arrabal S; Vargas A; Serrano A; Pavón FJ; Dieguez C; Nogueiras R; Rodríguez de Fonseca F; Suárez J
Acta Physiol (Oxf); 2018 Apr; 222(4):e13008. PubMed ID: 29193738
[TBL] [Abstract][Full Text] [Related]
6. CNS β
Richard JE; López-Ferreras L; Chanclón B; Eerola K; Micallef P; Skibicka KP; Wernstedt Asterholm I
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E344-E358. PubMed ID: 28588096
[TBL] [Abstract][Full Text] [Related]
7. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
de Souza CJ; Burkey BF
Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist.
Margareto J; Larrarte E; Marti A; Martinez JA
Biochem Pharmacol; 2001 Jun; 61(12):1471-8. PubMed ID: 11377376
[TBL] [Abstract][Full Text] [Related]
9. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer C; Gautier JF; Danforth E
Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
[TBL] [Abstract][Full Text] [Related]
10. Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.
Alemzadeh R; Karlstad MD; Tushaus K; Buchholz M
Metabolism; 2008 Nov; 57(11):1597-607. PubMed ID: 18940400
[TBL] [Abstract][Full Text] [Related]
11. Thermogenesis and related metabolic targets in anti-diabetic therapy.
Arch JR
Handb Exp Pharmacol; 2011; (203):201-55. PubMed ID: 21484574
[TBL] [Abstract][Full Text] [Related]
12. Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti- obesity lead compounds.
Tutone M; Lauria A; Almerico AM
Curr Pharm Des; 2014; 20(1):136-45. PubMed ID: 24180400
[TBL] [Abstract][Full Text] [Related]
13. [beta 3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs].
Sakura H; Togashi M; Iwamoto Y
Nihon Rinsho; 2002 Jan; 60(1):123-9. PubMed ID: 11808322
[TBL] [Abstract][Full Text] [Related]
14. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
Astrup A; Lundsgaard C
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
[TBL] [Abstract][Full Text] [Related]
15. Cryo-EM structures of the β
Nureki I; Kobayashi K; Tanaka T; Demura K; Inoue A; Shihoya W; Nureki O
Biochem Biophys Res Commun; 2022 Jun; 611():158-164. PubMed ID: 35489202
[TBL] [Abstract][Full Text] [Related]
16. Advances in pharmacotherapy for obesity.
Carruba M; Tomello C; Briscini L; Nisoli E
Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S13-6; discussion S17. PubMed ID: 9758239
[TBL] [Abstract][Full Text] [Related]
17. The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis.
Collins S; Surwit RS
Recent Prog Horm Res; 2001; 56():309-28. PubMed ID: 11237219
[TBL] [Abstract][Full Text] [Related]
18. Effects of ZD7114, a selective beta3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance.
Savontaus E; Pesonen U; Rouru J; Huupponen R; Koulu M
Eur J Pharmacol; 1998 Apr; 347(2-3):265-74. PubMed ID: 9653893
[TBL] [Abstract][Full Text] [Related]
19. Beta3-adrenergic regulation of leptin, food intake, and adiposity is impaired with age.
Kumar MV; Moore RL; Scarpace PJ
Pflugers Arch; 1999 Oct; 438(5):681-8. PubMed ID: 10555566
[TBL] [Abstract][Full Text] [Related]
20. Effect of a beta-3 agonist on food intake in two strains of rats that differ in susceptibility to obesity.
White CL; Ishihara Y; Dotson TL; Hughes DA; Bray GA; York DA
Physiol Behav; 2004 Sep; 82(2-3):489-96. PubMed ID: 15276814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
